The Ocular Immunology and Uveitis Foundation

Current Research


Anterior Segment Uveitis 

Eyegate EGP-437-006 


This is a prospective, multi-center, randomized, double-masked Phase 3 non-inferiority clinical trial designed to evaluate whether the study treatment (EGP-437) is non-inferior to the control treatment [prednisolone acetate ophthalmic suspension (1%)] to within a 10% margin in patients with non-infectious anterior segment uveitis. Patients will be randomly assigned in at 1:1 ratio to the treatment groups. Approximately 250 patients are sought for participation in this study at multiple sites. Learn More

Aciont DSPV-201


This is a randomized, parallel group, double-masked, active-controlled clinical trial to evaluate the efficacy, safety and tolerability of dexamethasone sodium phosphate Visulex (DSP-Visulex) system for the treatment of non-infectious anterior uveitis. Approximately 45 eligible subjects will be enrolled in this study. Learn More

Posterior, Intermediate, or Panuveitis

Novartis LFG316


This is a an open-label, multicenter, proof-of-concept study assessing the use of LFG316 in patients with active non-infectious intermediate-, posterior-, or panuveits. Approximately 25 patients with active disease are sought. Learn More

Santen Sirolimus DE-109 Injectable Study                                                               


This is a multinational, multicenter, randomized, double-masked study assessing the safety and efficacy of three doses of DE-109 (44 μg, 440 μg, 880 μg) administered every 2 months in subjects with active, non-infectious uveitis of the posterior segment of the eye.  Approximately 500 subjects with active, non-infectious posterior, intermediate or panuveitis will be enrolled at approximately 150 sites. Learn More

Long-term Follow-up

Bausch + Lomb 440

This is a phase 4, multi-center, observational study to investigate Fluocinolone Acetonide (FA)intravitreal implants (both the 0.59mg and 2.1mg) on corneal endothelial cell density. Patients with a FA intravitreal implant will visit clinic one (1) time for bilateral specular microscopy. Learn More

MUST Trial


The MUST trial is a randomized controlled clinical trial comparing two treatments for patients with vision-threatening non-infectious intermediate uveitis, posterior uveitis, or panuveitis: local therapy with fluocinolone acetonide intraocular implant in affected eyes; versus standard therapy: systemic corticosteroid therapy supplemented, when indicated, by corticosteroid-sparing potent immunomodulator therapy.

The initial portion of the study has concluded; all patients nationwide are now enrolled in the “Follow-Up” portion. As part of the clinical trial, patients had an unprecedented amount of clinical information collected longitudinally, which provides a starting point to evaluate the long-term outcomes of patients with these severe forms of uveitis. The objectives of the MUST Trial Follow-up Study are to evaluate long term consequences of the alternative treatment regimens and to conduct broad outcomes research in this well-documented cohort. Learn More

Other Research ongoing at the Foundation:

Characterization of inflammatory cytokines in the serum and intraocular fluid of patients with ocular inflammatory disease

This special interest study aims to correlate specific pathogenic cytokines found in serum and intraocular fluid with disease status, clinical remission, IMT-independent remission, and relapse.  Also, comparisons will be made between cytokine levels in serum and intraocular fluid.  This study is currently intended for birdshot retinochoroidopathy and sarcoidosis patients; BSRC and Sarcoid are both chronic inflammatory diseases of the eye, mainly affecting Caucasian women in their 50’s.  Sarcoidosis can also manifest systemically.  The significance of this study relates to the development of a clinical marker needed for testing to ensure remission, or disease inactivity.  Remission is important in order to prevent relapse; however, physicians require quantitative, definitive measures of remission status to improve patient outcomes.

Eligible patients will be diagnosed with birdshot retinochoroidopathy or sarcoidosis.  Patients undergoing major or minor intraocular surgical procedures will be contacted to inquire of their willingness to participate, to minimize unnecessary fluid withdrawals.  Withdrawal of intraocular fluid is routinely collected in these procedures and discarded; in the case of this study, the fluid would be analyzed.  Additionally, blood will be drawn from these patients.

Study participation is limited to one visit, and is paired with routine ocular visits and/or surgical procedures at MERSI.  No additional visits or tasks are required.